Vancouver, Canada – CDRD, Canada’s national life sciences venture, is pleased to announce an increased commitment to Sitka Biopharma with a $1.2M investment. This new investment will enable Sitka and its partner Cancer Research UK (CRUK) to accelerate critical development activities and rapidly enter clinical trials of STK-01, Sitka’s lead product for the treatment of […]

Vancouver, Canada: Sitka Biopharma is pleased to announce that Quark Venture Inc. and GF Securities, through their Global Health Sciences Fund (GHS), has invested  $1.9M into Sitka – financing that will enable the company to complete critical GLP toxicology studies and GMP manufacture of clinical drug product. This in turn will allow Sitka and partner […]

Sitka Biopharma Inc. is pleased to announce that Dr. Kristine Swiderek and Dr. Jack Geltosky have joined its Board of Directors. Dr. Kristine Swiderek is the Co-founder and Chief Scientific Officer of venture-backed OncoResponse, focusing in immuno-oncology. She brings deep expertise in clinical, R&D, partnering and alliance management to Sitka’s Board. Previously as CSO at […]

Quark Venture’s early investment in Sitka Biopharma helps the Vancouver-based company advance to clinical trials. We are pleased to announce the third and final tranche of a $2.4 million seed investment in Sitka Biopharma, a Vancouver-based company that is developing a new bladder cancer treatment.  This initial investment in Sitka Biopharma, announced April 2016, was […]

June 26, 2017 – Vancouver, BC and London, UK: An experimental treatment for bladder cancer will move into an early phase clinical trial under an agreement signed today between Cancer Research UK and Cancer Research Technology (CRT), the charity’s commercial arm, and Canadian biotechnology company Sitka Biopharma Inc., a spin-off of The Centre for Drug […]

On March 3, 2017 Rocket Builders announced its 15th annual “Ready to Rocket” lists.  These lists profile British Columbia technology companies that are best positioned to capitalize on the technology sector trends that will lead them to faster growth than their peers. The annual 2017 “Ready to Rocket” lists provide accurate predictions of private companies […]

Vancouver, Canada – April 13, 2016: Sitka Biopharma is pleased to announce that Quark Venture has made a significant seed investment in the company – a critical value-creating event that will enable Sitka to advance their lead compound for the treatment of bladder cancer into clinical trials. A spin-off of The Centre for Drug Research […]

Learn more about Sitka Biopharma’s unique approach to bladder cancer in International Innovation! Drs Helen Burt, Michael Parr, Richard Liggins and Clement discuss their promising discoveries with International Innovation magazine. The article in pdf can be accessed here: Sitka Biopharma International Innovation June 2015 edition.

Vancouver, Canada – December 3, 2013: CDRD Ventures Inc. (CVI), the commercialization vehicle of The Centre for Drug Research and Development (CDRD), announced today the launch of a new spin-off company, Sitka Biopharma Inc., a biotechnology company developing a new bladder cancer treatment. There are very limited effective chemotherapeutic treatments for intermediate and high-risk non-muscle […]